1. Galectin-1 and galectin-3 expression in equine mesenchymal stromal cells (MSCs), synovial fibroblasts and chondrocytes, and the effect of inflammation on MSC motility.
- Author
-
Reesink HL, Sutton RM, Shurer CR, Peterson RP, Tan JS, Su J, Paszek MJ, and Nixon AJ
- Subjects
- Animals, Cartilage, Articular cytology, Cartilage, Articular drug effects, Cartilage, Articular immunology, Cell Differentiation drug effects, Chondrocytes cytology, Chondrocytes immunology, Female, Fibroblasts cytology, Fibroblasts immunology, Galectin 1 antagonists & inhibitors, Galectin 1 immunology, Galectin 3 antagonists & inhibitors, Galectin 3 immunology, Gene Expression, Horses, Inflammation, Interleukin-1beta pharmacology, Lactose pharmacology, Lipopolysaccharides pharmacology, Male, Mesenchymal Stem Cells cytology, Mesenchymal Stem Cells immunology, Organ Specificity, Primary Cell Culture, Synovial Fluid cytology, Synovial Fluid drug effects, Synovial Fluid immunology, Synovial Membrane cytology, Synovial Membrane drug effects, Synovial Membrane immunology, Tumor Necrosis Factor-alpha pharmacology, Cell Movement drug effects, Chondrocytes drug effects, Fibroblasts drug effects, Galectin 1 genetics, Galectin 3 genetics, Mesenchymal Stem Cells drug effects
- Abstract
Background: Mesenchymal stromal cells (MSCs) can be used intra-articularly to quell inflammation and promote cartilage healing; however, mechanisms by which MSCs mitigate joint disease remain poorly understood. Galectins, a family of β-galactoside binding proteins, regulate inflammation, adhesion and cell migration in diverse cell types. Galectin-1 and galectin-3 are proposed to be important intra-articular modulators of inflammation in both osteoarthritis and rheumatoid arthritis. Here, we asked whether equine bone marrow-derived MSCs (BMSCs) express higher levels of galectin-1 and -3 relative to synovial fibroblasts and chondrocytes and if an inflammatory environment affects BMSC galectin expression and motility., Methods: Equine galectin-1 and -3 gene expression was quantified using qRT-PCR in cultured BMSCs, synoviocytes and articular chondrocytes, in addition to synovial membrane and articular cartilage tissues. Galectin gene expression, protein expression, and protein secretion were measured in equine BMSCs following exposure to inflammatory cytokines (IL-1β 5 and 10 ng/mL, TNF-α 25 and 50 ng/mL, or LPS 0.1, 1, 10 and 50 μg/mL). BMSC focal adhesion formation was assessed using confocal microscopy, and BMSC motility was quantified in the presence of inflammatory cytokines (IL-1β or TNF-α) and the pan-galectin inhibitor β-lactose (100 and 200 mM)., Results: Equine BMSCs expressed 3-fold higher galectin-1 mRNA levels as compared to cultured synovial fibroblasts (p = 0.0005) and 30-fold higher galectin-1 (p < 0.0001) relative to cultured chondrocytes. BMSC galectin-1 mRNA expression was significantly increased as compared to carpal synovial membrane and articular cartilage tissues (p < 0.0001). IL-1β and TNF-α treatments decreased BMSC galectin gene expression and impaired BMSC motility in dose-dependent fashion but did not alter galectin protein expression. β-lactose abrogated BMSC focal adhesion formation and inhibited BMSC motility., Conclusions: Equine BMSCs constitutively express high levels of galectin-1 mRNA relative to other articular cell types, suggesting a possible mechanism for their intra-articular immunomodulatory properties. BMSC galectin expression and motility are impaired in an inflammatory environment, which may limit tissue repair properties following intra-articular administration. β-lactose-mediated galectin inhibition also impaired BMSC adhesion and motility. Further investigation into the effects of joint inflammation on BMSC function and the potential therapeutic effects of BMSC galectin expression in OA is warranted.
- Published
- 2017
- Full Text
- View/download PDF